Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells.

scientific article published on 4 November 2015

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1051513399
P356DOI10.1186/2051-1426-3-S2-O5
P932PMC publication ID4646122

P50authorSaad S. KenderianQ45896559
Marco RuellaQ56947896
Simon F LaceyQ56978267
Stephan A GruppQ104495066
David L. PorterQ110797660
Carl H. JuneQ19277113
P2093author name stringJohn Scholler
Christopher A Hunter
Olga Shestova
David M Barrett
Farzana Nazimuddin
Saar Gill
Ted J Hofmann
Jan J Melenhorst
David A Christian
Jessica Perazzelli
P2860cites workChimeric antigen receptor T cells for sustained remissions in leukemiaQ29617588
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaQ29617590
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyQ34042800
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cellsQ37697847
CD123 and its potential clinical application in leukemias.Q38274851
P433issueSuppl 2
P921main subjectimmunotherapyQ1427096
P304page(s)O5-O5
P577publication date2015-11-04
P1433published inJournal for Immunotherapy of CancerQ27725163
P1476titleTreatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
P478volume3

Search more.